REFERENCES
- Dawson L, Tobin A, Smith P, Gorton T. Antimuscarinic anti-bodies in Sjogren's syndrome. Arthr Rheum. 2005;52:2984–95.
- Li J, Ha YM, Ku NY, et al. Inhibitory effects of autoantibodies on the muscarinic receptors in Sjogren's syndrome. Lab Invest. 2004;84 :1430–8.
- Scarselli M, Li B, Kim SK. Wess. Multiple residues in the second extracellular loop are critical for M3 muscarinic acetylcholine receptor activation. J Biol Chem. 2007;282: 7385–96.
- Naito Y, Matsumoto I, Wakamatsu E, et al. Muscarinic acetyl-choline receptor autoantibodies in patients with Sjogren's syn-drome. Ann Rheum Dis. 2005;64:510–1.
- Nakamura Y, Wakamatsu E, Matsumoto I, et al. High prevalence of autoantibodies to muscarinic-3 acetylcholine receptor in patients with juvenile-onset Sjogren's syndrome. Ann Rheum Dis. 2008;67:136–7.
- Koo NY, Li J, Hwang SM, et al. Functional epitopes of musca-rinic type 3 receptor which interacts with autoantibodies from Sjogren's syndrome patients. Rheumatology. 2008;47:828–33.
- Tsuboi H, Matsumoto I, Wakamatsu E, Nakamura Y, Iizuka M, Hayashi T, Goto D, Ito S, Sumida T. New epitopes and function of anti-M3 muscarinic acetylcholine receptor antibodies in patients with Sjogren's syndrome. Clin Exp Immunol. 2010;162: 53–61.
- Bacman SR, Berra A, Sterin-Borda L, Borda ES. Human primary Sjogren's syndrome autoantibodies as mediators of nitric oxide release coupled to lacrimal gland muscarinic acetylcholine receptors. Curr Eye Res. 1998;17:1135–42.
- Waterman SA, Gordon TP, Rischmueller M. Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neuro-transmission in Sjogren's syndrome. Arthr Rheum. 2000;43: 1647–54.
- Gao J, Cha S, Jonsson R, Opalko J, Peck AB. Detection of anti-type 3 muscarinic acetylcholine receptor antibodies in the sera of Sjogren's syndrome patients by use of a transfected cell line assay. Arthr Rheum. 2004;50: 2615–21.
- Marczinovits I, Kovacs L, Gyorgy A, Toth GK, Dorgai L, Molnar J, Pokorny G. A peptide of human muscarinic acetylcholine receptor 3 is antigenic in primary Sjogren's syndrome. J Au-toimmun. 2005;24: 47–54.
- Kovacs L, Marczinovits I, Gyorgy A, Toth GK, Dorgai L, Pal J, Molnar J, Pokorny G. Clinical associations of autoantibodies to human muscarinic acetylcholine receptor 3213-228 in primary Sjogren's syndrome. Rheumatology. 2005;44:1021–5.
- He J, Qiang L, Ding Y, Wei P, Li YN, Hua H, Li ZG. The role of muscarinic acetylcholine receptor type 3 polypeptide (M3RP205-220) antibody in the saliva of patients with primary Sjogren's syndrome. Clin Exp Rheumatol. 2012;30: 322–6.
- Cavill D, Waterman SA, Gordon TP. Antibodies raised against the second extracellular loop of the human muscarinic M3 receptor mimic functional autoantibodies in Sjogren's syndrome. Scand J Immunol. 2004;59: 261–6.
- Dawson LJ, Stanbury J, Venn N, Hasdimir B, Rogers SN, Smith PM. Antimuscarinic antibodies in primary Sjogren's syndrome reversibly inhibit the mechanism of fluid secretion by human submandibular salivary acinar cells. Arthr Rheum. 2006;54: 1165–73.
- Tsuboi H, Nakamura Y, Iizuka M, Matsuo N, Matsumoto I, Sumida T. Generation and functional analysis of monoclonal antibodies against the second extracellular loop of human M3 muscarinic acetylcholine receptor. Mod Rheumatol. 2012;22:264–71.
- Jin M, Hwang S-M, Davies AJ, Shin Y, Bae J-S, Lee J-H, Lee EB, Song YW, Park K. Autoantibodies in primary Sjogren's syndrome patients induce internalization of muscarinic type 3 receptors. Biochim Biophys Acta. 2012;1822:161–7.